

C' chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-pentylurea, N-(sec-Butyl)-N'-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea, N-allyl-N'-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea, and N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'(2-propynyl)urea or a pharmaceutically acceptable salt of solvate thereof.

61. (New) The compound according to Claim 60, wherein said compound is N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-propylurea or a pharmaceutically acceptable salt of solvate thereof.

62. (New) The compound according to Claim 60, wherein said compound is N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-ethylurea or a pharmaceutically acceptable salt of solvate thereof.

63. (New) The compound according to Claim 60, wherein said compound is N-butyl-N'-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea or a pharmaceutically acceptable salt of solvate thereof.

64. (New) The compound according to Claim 60, wherein said compound is N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-pentylurea or a pharmaceutically acceptable salt of solvate thereof.

65. (New) The compound according to Claim 60, wherein said compound is N-(sec-Butyl)-N'-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea or a pharmaceutically acceptable salt of solvate thereof.

C' 66. (New) The compound according to Claim 60, wherein said compound is N-allyl-N'-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea or a pharmaceutically acceptable salt of solvate thereof.

67. (New) The compound according to Claim 60, wherein said compound is N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'(2-propynyl)urea or a pharmaceutically acceptable salt of solvate thereof.

68. A method for treating a disease selected from the group consisting of malignant tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, comprising

administering an effective amount of the compound according to Claim 1 or a pharmaceutically or solvate thereof, together with a pharmaceutically acceptable carrier, to a mammal.

69. (New) The method of claim 68, wherein the disease is Kaposi's sarcoma.

70. (New) A method for inhibiting the angiogenesis of a target blood vessel, comprising

contacting the compound according to Claim 1 or a pharmaceutically acceptable salt or solvate thereof with a vascular endothelial cell of the target blood vessel, wherein

said target blood vessel is at least one blood vessel that is involved in feeding at least one tissue causative of at least one disease that is selected from the group consisting of a tumor tissue, retinopathy tissue, and rheumatism tissue.--